209 related articles for article (PubMed ID: 35019948)
41. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort.
Hwang SJ; Carlos G; Wakade D; Byth K; Kong BY; Chou S; Carlino MS; Kefford R; Fernandez-Penas P
J Am Acad Dermatol; 2016 Mar; 74(3):455-61.e1. PubMed ID: 26793994
[TBL] [Abstract][Full Text] [Related]
42. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.
Sibaud V
Am J Clin Dermatol; 2018 Jun; 19(3):345-361. PubMed ID: 29256113
[TBL] [Abstract][Full Text] [Related]
43. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
[TBL] [Abstract][Full Text] [Related]
44. Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience.
Vitale G; Lamberti G; Comito F; Di Nunno V; Massari F; Morelli MC; Ardizzoni A; Gelsomino F
Expert Opin Biol Ther; 2020 Sep; 20(9):1047-1059. PubMed ID: 32425081
[TBL] [Abstract][Full Text] [Related]
45. Effect of dermatological consultation on survival in patients with checkpoint inhibitor-associated cutaneous toxicity.
Thompson LL; Li EB; Krasnow NA; Chang MS; Said JT; Molina GE; Polyakov NJ; Yoon J; Dee EC; Huang K; Blum AE; Kuchroo JR; Hinton AN; Reynolds KL; Chen ST
Br J Dermatol; 2021 Sep; 185(3):627-635. PubMed ID: 33733456
[TBL] [Abstract][Full Text] [Related]
46. Increased risk of cutaneous immune-related adverse events in patients treated with talimogene laherparepvec and immune checkpoint inhibitors: A multi-hospital cohort study.
Leung BW; Wan G; Nguyen N; Rashdan H; Zhang S; Chen W; Cohen S; Boland GM; Sullivan RJ; Fadden RM; Kaufman HL; Kwatra SG; LeBoeuf NR; Semenov YR
J Am Acad Dermatol; 2023 Jun; 88(6):1265-1270. PubMed ID: 36944564
[TBL] [Abstract][Full Text] [Related]
47. Association between immune checkpoint inhibitor medication and uveitis: a population-based cohort study utilizing TriNetX database.
Kuo HT; Chen CY; Hsu AY; Wang YH; Lin CJ; Hsia NY; Tsai YY; Wei JC
Front Immunol; 2023; 14():1302293. PubMed ID: 38264654
[TBL] [Abstract][Full Text] [Related]
48. Immune cell subsets in interface cutaneous immune-related adverse events associated with anti-PD-1 therapy resemble acute graft versus host disease more than lichen planus.
Almodovar Cruz GE; Kaunitz G; Stein JE; Sander I; Hollmann T; Cottrell TR; Taube JM; Sunshine JC
J Cutan Pathol; 2022 Aug; 49(8):701-708. PubMed ID: 35445765
[TBL] [Abstract][Full Text] [Related]
49. Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis.
Duan J; Cui L; Zhao X; Bai H; Cai S; Wang G; Zhao Z; Zhao J; Chen S; Song J; Qi C; Wang Q; Huang M; Zhang Y; Huang D; Bai Y; Sun F; Lee JJ; Wang Z; Wang J
JAMA Oncol; 2020 Mar; 6(3):375-384. PubMed ID: 31876895
[TBL] [Abstract][Full Text] [Related]
50. The prediction potential of neutrophil-to-lymphocyte ratio for the therapeutic outcomes of programmed death receptor-1/programmed death ligand 1 inhibitors in non-small cell lung cancer patients: A meta-analysis.
Huang Y; Shen A
Medicine (Baltimore); 2020 Aug; 99(34):e21718. PubMed ID: 32846790
[TBL] [Abstract][Full Text] [Related]
51. Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States.
Jain P; Gutierrez Bugarin J; Guha A; Jain C; Patil N; Shen T; Stanevich I; Nikore V; Margolin K; Ernstoff M; Velcheti V; Barnholtz-Sloan J; Dowlati A
ESMO Open; 2021 Oct; 6(5):100252. PubMed ID: 34461483
[TBL] [Abstract][Full Text] [Related]
52. Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: A systematic review and meta-analysis.
Mori K; Pradere B; Quhal F; Katayama S; Mostafaei H; Laukhtina E; Schuettfort VM; D'Andrea D; Egawa S; Bensalah K; Schmidinger M; Powles T; Shariat SF
Cancer Treat Rev; 2021 Sep; 99():102242. PubMed ID: 34153830
[TBL] [Abstract][Full Text] [Related]
53. Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort.
Brosseau S; Danel C; Scherpereel A; Mazières J; Lantuejoul S; Margery J; Greillier L; Audigier-Valette C; Gounant V; Antoine M; Moro-Sibilot D; Rouquette I; Molinier O; Corre R; Monnet I; Langlais A; Morin F; Bergot E; Zalcman G; Levallet G
Clin Lung Cancer; 2019 Sep; 20(5):e564-e575. PubMed ID: 31279641
[TBL] [Abstract][Full Text] [Related]
54. Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression.
Masuda K; Horinouchi H; Tanaka M; Higashiyama R; Shinno Y; Sato J; Matsumoto Y; Okuma Y; Yoshida T; Goto Y; Yamamoto N; Ohe Y
J Cancer Res Clin Oncol; 2021 Jan; 147(1):245-251. PubMed ID: 32705363
[TBL] [Abstract][Full Text] [Related]
55. Association of age with survival in older patients with cutaneous melanoma treated with immune checkpoint inhibitors.
Howell AV; Gebregziabher M; Thiers BH; Graboyes EM; Paulos CM; Wrangle JM; Hunt KJ; Wallace K
J Geriatr Oncol; 2022 Sep; 13(7):1003-1010. PubMed ID: 35660090
[TBL] [Abstract][Full Text] [Related]
56. Prognostic role of programmed cell death ligand-1 expression in head and neck cancer treated with programmed cell death protein-1/programmed cell death ligand-1 inhibitors: A meta-analysis based on clinical trials.
Huang Z; Zheng S; Ding S; Wei Y; Chen C; Liu X; Li H; Xia Y
J Cancer Res Ther; 2021 Jul; 17(3):676-687. PubMed ID: 34269299
[TBL] [Abstract][Full Text] [Related]
57. Comparative efficacy and safety of PD-1/PD-L1 Inhibitors versus platinum-based chemotherapy for the first-line treatment of advanced non-small cell lung cancer: a meta analysis of randomized controlled trials.
Li ZQ; Yan HC; Gu JJ; Yang YL; Zhang MK; Fang XJ
Pharmacol Res; 2020 Oct; 160():105194. PubMed ID: 32937178
[TBL] [Abstract][Full Text] [Related]
58. Cutaneous immune-related adverse events: incidence rates, risk factors and association with extracutaneous toxicity. A prospective study of 189 patients treated with checkpoint inhibitors in a Spanish tertiary care hospital.
Juan-Carpena G; Martínez Banaclocha N; Palazón-Cabanes JC; Niveiro-de Jaime M; Betlloch-Mas I; Blanes-Martínez M
Clin Exp Dermatol; 2024 Feb; ():. PubMed ID: 38372424
[TBL] [Abstract][Full Text] [Related]
59. Association of Bullous Pemphigoid With Immune Checkpoint Inhibitor Therapy in Patients With Cancer: A Systematic Review.
Asdourian MS; Shah N; Jacoby TV; Reynolds KL; Chen ST
JAMA Dermatol; 2022 Aug; 158(8):933-941. PubMed ID: 35612829
[TBL] [Abstract][Full Text] [Related]
60. Programmed Death-Ligand 1 and Programmed Death-Ligand 2 mRNAs Measured Using Closed-System Quantitative Real-Time Polymerase Chain Reaction Are Associated With Outcome and High Negative Predictive Value in Immunotherapy-Treated NSCLC.
Fernandez AI; Gavrielatou N; McCann L; Shafi S; Moutafi MK; Martinez-Morilla S; Vathiotis IA; Aung TN; Yaghoobi V; Bai Y; Chan YG; Weidler J; Herbst R; Bates M; Rimm DL
J Thorac Oncol; 2022 Sep; 17(9):1078-1085. PubMed ID: 35764237
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
